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Novelty and impact 
This is a nationwide, population-based registry study with detailed data on exposure. Our results 
support an association between maternal diabetes and childhood cancer in the offspring. We found 
the risk of cancer among the offspring to be elevated, especially for those born to mothers with 
gestational diabetes and highest for leukemias and some solid tumors.  As a novel finding, our study 
suggests a trend towards a risk-reducing impact of maternal diabetes medication. 
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Abbreviations: 
AGA= Appropriate for gestational age 
CI= Confidence interval 
CNS= Central nervous system 
DM = Diabetes mellitus 
FCR= Finnish Cancer Registry 
HILMO= Care Registry for Health Care 
IGF-1= Insulin-like Growth Factor 1  
Kela= Social Insurance Institute of Finland 
LGA= Large for gestational age 
MBR= Medical Birth Registry 
OR= Odds ratio 
SGA= Small for gestational age 
THL= National Institute for Health and Welfare 
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Abstract 
An association between maternal diabetes, its medication and childhood cancer has not been 
previously explored in a registry-based setting. With a case-control design, we aimed to explore 
whether maternal diabetes is associated with an increased risk of childhood cancer in the offspring. 
Combining data from population-based registries, we analyzed a total of 2,029 cases, i.e. persons 
with childhood cancer diagnosed under the age of 20 years between years 1996-2014 and a total of 
10,103 matched population controls. The mothers of the cases/controls and their diagnoses of 
diabetes (DM) before/during pregnancy as well as their insulin/metformin prescriptions during 
pregnancy were identified. Conditional logistic regression modelling was used to analyze the risk of 
childhood cancer. The OR for childhood cancer among those exposed to any maternal diabetes was 
1.32 (95% CI 1.14-1.54) compared to the offspring of the non-diabetic mothers. The effect of 
maternal diabetes on the risk of childhood cancer remained elevated even after adjusting for 
maternal age, parity and smoking. Our data suggest that maternal diabetes medication may reduce 
the risk for childhood cancer (adjusted OR 0.83, 95% CI 0.36-1.94), especially in gestational diabetes 
(adjusted OR 0.26, 95% CI 0.05-1.25), compared to the diabetic mothers without medication. The 
risk of childhood leukemia was significantly higher among children exposed to any maternal diabetes 
(OR 1.36, CI 1.04-1.77) compared to the unexposed. Maternal diabetes appears to be associated 
with an increased risk of childhood cancer in the offspring. The possible risk-reducing effect of an 
exposure to diabetes medication on offspring cancer risk warrants further investigation. 
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Introduction 
The early onset of childhood cancer implicates etiological involvement of both genetic factors and/or 
early (pre- and perinatal) environmental exposures. However, to date, evidence suggests only an 
estimated fraction of 5-10% of childhood cancer to be explained by identified, hereditary cancer 
syndromes.1,2 As the bulk of epidemiological data supports a significant causal role for environmental 
exposures in the risk of a wide range of cancer,3-6  there is an obvious need to evaluate the role of 
early exposures in the etiology of childhood cancer.  
  
The risk of adult cancer has been shown to be elevated among patients with type 1 or 2 diabetes.7,8 
For type 2 diabetes, the increased risk is observed regardless of confounding factors,7,9,10 such as 
obesity, a widely recognized risk factor for cancer.11 The potential contributors to the increased risk 
among diabetics are many, including at least hyperglycemia and -insulinism affecting all tissues, as 
well as site-specific mechanisms affecting certain organs, i.e. the liver and pancreas, through 
oxidative stress. These increase the amount of insulin receptors, overexpressed in cancer cells, 
altering growth, but also potential contributors like IGF-1 receptors, inducing cancer cell growth 
selectively.10,12-15   Both endo- and exogenous hyperinsulinism increase the risk of cancer.12-14,16  There 
are data suggesting that type 2 diabetes medication, especially metformin, may contribute to a 
decrease in the risk of cancer in diabetes patients.17,18 
  
Maternal type 1, 2 and gestational diabetes all appear to have an association with childhood cancer 
in the offspring.19-22 The association between maternal diabetes and childhood cancer is  most 
convincing for acute lymphoblastic leukemia (ALL),22,23 but with only few studies differentiating 
pregestational from gestational diabetes.19,21,23-24 Whether modifiable factors affecting the 
anthropometrics at birth, such as maternal diabetes and diabetes medication, may impact childhood 
carcinogenesis, remains to be delineated.  
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Our aim was, in a population-based registry setting, and using a case-control design, to study 
whether maternal diabetes and its medication are associated with the risk of childhood and 
adolescent cancer in the offspring. As an additional exposure, we explored the association of birth 
weight with childhood cancer risk. 
  
Materials and methods 
 We used the key Finnish, nationwide registries described below and in Appendix 1.A unique 
personal identity code, given to each Finnish citizen since 1967 allows a linkage of information 
between the different health registries. The Finnish Cancer Registry (FCR) was founded in 1952 and 
commenced systematic, nationwide registration of cancer in 1953. The FCR includes data on 
patients, cancer, treatments and causes of death. The FCR has 95% overall coverage.25 
  
The ongoing Drugs and Pregnancy -project (1996 onwards) has compiled data from several national 
health registers: the Medical Birth Register (MBR), Register on Induced Abortions and that on 
Congenital Malformations (all maintained by the National Institute for Health and Welfare, THL) as 
well as the Register on Reimbursed Drug Purchases and that on Medical Special Reimbursements 
maintained by the Social Insurance Institute of Finland (Kela). This project was designed to evaluate 
the pattern of drug use during pregnancy and estimate the impact of medication on pregnancy 
outcomes. The material is cumulatively supplemented on a biannual basis. 
The Care Register for Health Care (HILMO) is maintained by THL from the year 1994 onwards. It is a 
continuation of the preceding Hospital Discharge Register (1969-1993). Currently, HILMO contains 
data on patients discharged from inpatient care (since 1969), on day surgeries (since 1994) and on 
hospital outpatient visits in public hospitals (since 1998).  
With the study being fully registry -based, no ethical board approval was required. The respective 
research permits from THL, Kela and Helsinki University Hospital for this study have been obtained.    
Study population 
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All births during the years 1996-2014 were identified through the MBR (n=1 108 754). By then linking 
to the Finnish Cancer Registry we identified our cases, defined as all subjects diagnosed with cancer 
under the age of 20 years (n=2,037). From the MBR, we then identified five birthyear and sex-
matched population controls for each case (n=10,185). The medical information on the mothers and 
children was obtained from the HILMO and the MBR. The mothers of the cases and controls, 
diagnosed with pregestational diabetes prior to pregnancy, or with gestational diabetes during 
pregnancy, and those with insulin and/or metformin medication during pregnancy, were identified. 
Due to missing data on birth weight or gestational age of the offspring a total of 8 cases and 82 
controls were excluded from the analysis as described in Figure 1. The key demographics of the 
groups are given in Table 1. 
Exposure definition and classification 
The mothers with offspring exposed to pregestational or gestational diabetes were identified with 
the maternal ICD- codes (versions ICD-9 and ICD-10). With the ICD-10 we used the diabetes codes 
E10-E14 and O24.0, O24.1, O24.4 and O24.9, and for ICD-9 codes 250, i6480A and i6488A were used. 
Pregestational diabetes was defined as a diagnosis any time before pregnancy, and gestational 
diabetes as a diagnosis given between the beginning of pregnancy and delivery. The date of 
conception was calculated as the date of delivery minus the gestational age at birth in days based on 
the best clinical estimate (the majority with ultrasound confirmation), and as registered in the MBR. 
Additional information on possible diabetes exposure of the offspring was gathered from the MBR 
data on pathological glucose tolerance test(s) during pregnancy and/or the MBR diabetes record, 
and from the drug reimbursement codes from Kela. The diabetes medication was identified with the 
ATC-codes A10A for insulin and A10B for metformin. More detailed information on the diabetes 
classification used is provided in Appendix 2.   
Information on birth weight was retrieved from the MBR and categorized as children born weighing 
> or ≤ 4000g. Birth weight was also related to the gestational age and categorized as small (SGA), 
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appropriate (AGA) or large for gestational age (LGA). SGA was defined as birth weight under -2 SD 
and LGA over +2 SD of the standard population- based growth-curves.26 
Outcome definition and classification 
The outcome was defined as being diagnosed with first cancer by the age of 20 years. Cancer was 
defined as a malignant neoplasm, but also including benign or borderline tumors of the central 
nervous system (CNS). The Finnish Cancer Registry uses both the ICD-0-3 and ICCC3 classification27 to 
classify childhood cancers. Malignancies were classified using the ICCC3 code 011 for ALL, 011-015 
for all leukemias, 021-025 for lymphomas, 031-036 for CNS tumors and 041-122 for other cancers. 
Statistical analysis 
Conditional logistic regression modelling was applied to estimate the odds ratios for childhood 
cancer comparing children of diabetic mothers to those of healthy mothers. The risk of childhood 
cancer in the offspring was also evaluated separately for pregestational and gestational diabetes as 
well as type of diabetes medication (insulin/metformin). In addition to the crude odds ratios, we also 
fitted a model adjusting for maternal age (< 25, 25-29, ≥ 30 years), parity (1st,2nd, ≥ 3rd), and smoking 
(yes/no). Cases/controls with missing data on maternal smoking were omitted from the analysis. The 
reference maternal age was set at 25-29 years at delivery. For parity we chose the first child to be 
the reference category. The association between birth weight and risk of childhood cancer was first 
assessed for data validation. As birth weight is considered a mediator for childhood cancer, it was 
not included in the analyses. A sensitivity analysis including maternal pre-pregnancy BMI was 
conducted restricting data to the years 2004-2014 as the MBR began collecting information on 
maternal weight and height in 2004.  Statistical analyses were performed with STATA MP14 
(StataCorp LLC). Additional analyses stratifying by cancer subtypes were also performed.   
Data Availability  
The data that support the findings of this study are available upon request from the corresponding 
author. The data are not publicly available due to privacy or ethical restrictions. 
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Results 
We found the risk of childhood cancer to be significantly increased among the offspring exposed to 
any type of maternal diabetes compared to those not exposed (crude OR 1.32, 95% CI 1.14-1.54). 
The risk remained elevated even after adjusting for age, parity and the smoking status of the mother 
(adjusted OR 1.28 95% CI 1.10-1.50). After adjustment, the risk was elevated among those exposed 
to gestational (adjusted OR 1.31, 95% CI 1.11-1.54), but not among those exposed to pregestational 
diabetes (adjusted OR 1.11, 95% CI 0.73-1.69). 
  
The adjusted odds ratio for childhood cancer in the offspring exposed to maternal diabetes without 
medication was 1.31 (95%CI 1.11-1.55). The risk estimates for childhood cancer seemed to be lower 
following exposure to maternal diabetes with metformin medication (crude OR 0.99, 95% CI 0.46-
2.15, adjusted OR 1.04,95% CI 0.48-2.27). Metformin was taken by 10 mothers in the case and 50 
mothers in the control group. Other associations with diabetes medication compared to non-
diabetic mothers were inconclusive. For further results, see Table 2. A sensitivity analysis, including 
an adjusted model with maternal pre-pregnancy BMI, yielded a slightly higher risk (Appendix 3).  
  
We also performed an additional analysis comparing the risk for childhood cancer in the offspring, if 
the diabetic mother was receiving diabetes medication or not. Maternal diabetes medication 
seemed to lower the risk estimates for childhood cancer (adjusted OR 0.83, 95% CI 0.36-1.94), 
especially for gestational diabetes (adjusted OR 0.26, 95% CI 0.05-1.25) (Table 3). For the 
pregestational diabetes the sufficient data was not available due to matched analysis model.  
  
In our analyses by cancer subtype, a possible association between an exposure to any maternal 
diabetes and childhood leukemia in the offspring was found (crude OR 1.36, 95% CI 1.04-1.77, 
adjusted OR 1.31, 95% CI 1.00-1.72). The risk for ALL following exposure of maternal pregestational 
diabetes was twofold compared to the offspring of non-diabetic mothers (adjusted OR 2.10, 95% CI 
1.05-4.21) (Table 4). 
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Yet, we did find a significant association (adjusted OR 1.35, CI 1.04-1.77) (Table 4) between the 
exposure to gestational diabetes and pediatric solid tumors other than CNS (other cancers) with the 
two largest groups being neuro- and nephroblastomas (20,2% and 15,8%) (data not shown). When 
adjusting for maternal age, birth order of the child and maternal smoking, the results were not 
altered. The results by cancer type are presented in Table 4. 
  
To cross-validate our data against previously published studies, we also explored the association 
between birth weight, without information on maternal diabetes, and childhood cancer of the 
offspring. We found those with a high birth weight (over 4000g) to have an increased risk for 
childhood ALL (adjusted OR 1.34, 95% CI 1.06-1.69) as well as all leukemias adjusted OR 1.30, 95% CI 
1.06-1.60) (data not shown). 
Discussion 
Our aim was to study maternal diabetes, its medication and their possible impact on the risk of 
childhood cancer. We found a significant association between fetal exposure to gestational diabetes 
and the risk of childhood cancer. Our data also demonstrated an elevated risk of childhood leukemia 
and some solid tumors among the offspring following maternal diabetes exposure. 
  
In a study reporting on data from the California Cancer Registry, an association between several 
childhood cancer types in the offspring and maternal diabetes and obesity prior to pregnancy was 
observed. Excessive maternal weight gain during pregnancy also appeared to be a risk factor.24 A 
population-based, cohort study in Sweden, showed a 1.6-fold increase in the risk of childhood 
leukemia by maternal type 1 and gestational diabetes, but with lack of an association between 
gestational diabetes and central nervous system malignancies (CNS).22 For other cancers, the results 
were inconclusive due to a small number of cases. Results from a recent Danish study exploring the 
influence of maternal diabetes on the risk of childhood ALL found the risk to be increased by at least 
2-fold.23 
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Our results support an association between gestational diabetes and childhood cancer in  the 
offspring.20,21 Furthermore, we re-established the significant association between maternal diabetes 
and childhood leukemia, in concordance with previous studies.22,28 In our study the risk for ALL 
seemed to be increased in offspring exposed to maternal pregestational diabetes. Importantly, and 
following more accurate exposure definition and classification with multiple information sources, we 
found the risk for any childhood cancer to be increased especially for gestational diabetes.23 
  
Previous studies including data on maternal medication have been hampered by  small sample 
size,19,23 or have not included the possible impact of medication in the  analyses.20-22,24,28  Despite the 
small sample size, our data  do suggest  a possible risk-reducing impact of maternal medication for 
gestational diabetes on the incidence of childhood cancer in the offspring. This impact was also 
discernible for any diabetes but especially for gestational diabetes, and was most pronounced when 
metformin was used, reducing the risk to the population level.  Based on our data, further studies on 
the possibility of a true, protective effect rendered by diabetes medication appear warranted.  
  
Possible biological mechanisms linking maternal diabetes and the emergence of childhood cancer in 
the offspring are many. First, maternal hyperglycemia is known to affect the epigenetics of the 
offspring.29 Second, maternal hyperglycemia, and especially hyperinsulinism, increase the expression 
of insulin receptors, particularly on cancer cells, as well as the production of  IGF-1.10,12-15 Third, 
hyperinsulinism can be iatrogenic or endogenous.12-14,16 These biological mechanisms may lie behind 
our findings. In gestational diabetes, insulin resistance emerges during pregnancy and increases the 
amount of insulin and IGF-1 receptors through the impact of hyperglycemia.30 In pregestational 
diabetics, the medication has often been initiated years before thus rendering the mother with a 
more stable glucose homeostasis, at least in early pregnancy, compared to those with gestational 
diabetes. Yet, medication for gestational diabetes most likely improves maternal glucose 
homeostasis and thus reduce fetal exposure to hyperglycemia.  
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The association between birth weight and childhood cancer, especially ALL, has been widely 
recognized.31-34 Our results remain in line with those of previous studies and serve to further 
corroborate the data. A high birth weight and excessive fetal growth are both associated with a 
higher IGF-1, all known risk factors for childhood cancer, especially ALL.12,35-38 Birth weight may thus 
be considered a mediator for the biological impact of maternal diabetes on the risk of cancer in the 
offspring.  
  
The prevalence of gestational diabetes has been estimated to be around 10-13% in Finland 
(unpublished data from MBR, shown in the national gestational diabetes guidelines) with that of 
diabetes reportedly lying at about 11% among women overall.39 In our data, the prevalence of 
diabetes was slightly lower, at 9.7%. Most likely our material lacks a group of pregestational and 
gestational diabetes patients treated in an outpatient setting with dietary counseling only. Another 
pitfall is that neither do we have information on glucose homeostasis before and during pregnancy 
nor on the dose-specific drug exposure. These may differ in pregestational and gestational diabetes 
and thus our results by type of diabetes are to be viewed with some caution. Also, a possibility of 
misclassification bias or underestimation of the number of diabetes patients with the transfer from 
the ICD-9 to ICD-10 exists.   
  
Our nationwide and population-based study combines an exceedingly comprehensive set of 
information on maternal morbidity, perinatal history and cancers among the offspring before the 
child´s 20th birthday. In the setting of maternal diabetes and the risk for cancer at an early age, our 
study is the first to suggest a possible, risk-reducing effect posed by the medication shedding 
additional light on the background of a putative, biological association between the two.20-23 
  
Conclusion 
Our comprehensive, nationwide, registry-based data, free of recall and selection bias, is strongly 
indicative of a link between maternal diabetes and the risk of childhood cancer in the offspring, 
especially that of leukemia and some solid tumors, for which the underlying biological mechanisms 
This article is protected by copyright. All rights reserved.
  
remain to be delineated. A possible, risk-reducing impact rendered by the pharmacotherapy of 
maternal diabetes on the risk of childhood cancer in the offspring remains to be established. 
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Table 1. Baseline characteristics of cases and controls in years 1996-2014. 
 
 
 
 
 
 
  
Maternal characteristics      
Age of the mother (median) 30 15-48 29 14-47 0 
First child 847 41.7 4,098 40.6 0/4 
Smoking      
     Yes 291 14.3 1,447 14.3 0 
     No 1,680 82.8 8,404 83.2 0 
     Unknown 58 2.9 252 2.5 0 
Diabetes diagnosis*  241 11.9 940 9.3 0 
Pregestational diabetes** 29 1.4 128 1.3 0 
          Gestational diabetes*** 212 10.4 812 8 0 
Any diabetes medication 33 1.6 154 1.5 0 
Diabetes medication: insulin 25 1.2 114 1.1 0 
       Diabetes medication: 
 
10 0.5 50 0.5 0 
        Diabetes medication: both 2 0 10 0 0 
Offspring characteristics      
Female 937 46.1 4,672 46.2 0 
Male 1,092 53.8 5,431 53.8 0 
Gestational age, weeks (mean) 39 24-43 39 24-42 0 
Birth weight (mean) 3,532 825-5,200 3,521 485-5,750 0 
Birth weight ≥4000g 400 19.7 1,870 18.5 0 
Birth weight <4000g 1,629 80.3 8,233 81.5 0 
Gestational age ≥37 weeks 1,888 93.1 9,566 94.7 0 
Gestational age <37 weeks 141 6.9 537 5.3 0 
Birth weight by gestational age      
SGA 55 2.7 217 2.1 0 
AGA 1,881 92.7 9,587 94.9 0 
LGA 93 4.6 299 3 0 
Twins 67 3.3 319 3.2 0 
*Any diabetes diagnosis gathered from MBR, HILMO or Drugs and pregnancy- database. 
**Diagnoses E10-E14, O24.0-24.3, i259, i6480a, medical reimbursement code. ***Diagnoses O24.4, O24.9, i6488A, or pathological glucose tolerance test. 
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  Cases 
n=2,029 
Proportion (%) 
or range 
Controls  
n=10,103 
Proportion (%)  
or range 
Missing 
values:  
Cases/controls 
 
Cases 
N= 2,029 
(%) 
Controls 
N= 10,103 
(%) 
Crude 
OR* 95% CI 
Adjusted 
OR** 95% CI 
Any maternal 
diabetes 241(11.9) 940 (9.3) 1.32 1.14-1.54 1.28 1.10-1.50 
Any diabetes 
medication 33 (1.6) 154 (1.5) 1.14 0.77-1.67 1.12 0.76-1.67 
Insulin only 23(1.1) 104 (1.0) 1.16 0.73-1.85 1.13 0.70-1.82 
       Metformin only 8 (0.4) 40 (0.4) 0.99 0.46-2.15 1.04 0.48-2.27 
Insulin and    
metformin 2(0.1) 10(0.1) 1.57 0.32-7.80 1.41 0.28-7.02 
Diabetes without 
medication 208 (10.2) 786 (7.8) 1.35 1.15-1.59 1.31 1.11-1.55 
Gestational 
diabetes 212(10.4) 812(8.0) 1.35 1.14-1.58 1.31 1.11-1.54 
Any diabetes 
medication 12(0.6) 84(0.8) 0.80 0.43-1.50 0.84 0.45-1.58 
Pregestational 
diabetes 29 (1.4) 128 (1.2) 1.14 0.76-1.72 1.11 0.73-1.69 
Any diabetes 
medication 21(1.0) 70(0.7) 1.51 0.92-2.49 1.43 0.86-2.37 
*Matched analysis without adjustment. **Matched analysis adjusted by maternal age, parity, smoking status. 
  
Table 2. Odds ratios of childhood cancer of the offspring, stratified by medication, compared to offspring of a 
non-diabetic mother. 
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Any maternal diabetes N=241 (%) N=940 (%)     
   Any diabetes medication       33 (13.7)  154 (16.4) 0.61 0.28-1.33 0.83 0.36-1.94 
Pregestational diabetes N=29(%) N= 128 (%)     
   Any diabetes medication  21(72.4) 70(54.7) - - - - 
Gestational diabetes N=212(%) N=812(%)     
   Any diabetes medication 12(5.7) 84(10.3) 0.20 0.04 – 0.88 0.26 0.05 – 1.25 
*Matched analysis without adjustment. **Matched analysis adjusted by maternal age, parity, smoking status.  
 -No sufficient data for matched analysis. 
  
Table 3. Odds ratios of childhood cancer after exposure of maternal diabetes with medication, compared to 
maternal diabetes with no medication.  
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Diabetes type Cases Controls Crude OR* 95%CI 
Adjusted 
OR** 
95% CI 
Cancer subtypes 
Cases 
N=2,029 
(%) 
Controls 
N=10,103 
(%) 
Crude 
OR* 
95% CI 
Adjusted 
OR** 
95% CI 
ALL   511 (25.2) 2,544 (25.2)         
Any maternal diabetes  61 (11.9) 247 (9.7) 1.27 0.94-1.72 1.23 0.90-1.68 
Pregestational diabetes  12 (2.3) 30 (1.2) 1.97 0.99-3.89 2.10 1.05-4.21 
Gestational diabetes  49 (9.6) 217 (8.8) 1.16 0.83-1.62 1.10 0.78-1.55 
All leukemias 649 (32.0) 3,230 (32.0)         
Any maternal diabetes 80 (12.3) 306 (9.5) 1.36 1.04-1.77 1.31 1.00-1.72 
Pregestational diabetes 12 (1.8) 40 (1.2) 1.49 0.77-2.87 1.56 0.80-3.04 
Gestational diabetes 68 (10.5) 266 (8.2) 1.33 1.00-1.77 1.26 0.94-1.70 
Lymphomas 149 (7.3) 740 (7.3)         
Any maternal diabetes 14 (9.4) 49 (6.6) 1.47 0.78-2.78 1.29 0.66-2.50 
Pregestational diabetes 0 (0) 10 (1.4) _ _ _ _ 
Gestational diabetes 14 (9.4) 39 (5.3) 1.80 0.95-3.41 1.59 0.81-3.12 
CNS 484 (23.9) 2,407 (23.8)         
Any maternal diabetes 56 (11.6) 230 (9.6) 1.24 0.91-1.70 1.23 0.89-1.69 
Pregestational diabetes 8 (1.7) 27 (1.1) 1.47 0.66-3.28 1.37 0.61-3.06 
Gestational diabetes 48 (9.9) 203 (8.4) 1.19 0.86-1.67 1.19 0.85-1.68 
Other cancers 743 (36.6) 3,706 (36.7)         
Any maternal diabetes 89 (12.0) 355 (9.6) 1.29 1.00-1.66 1.27 0.98-1.64 
Pregestational diabetes 9 (1.2) 51 (1.4) 0.93 0.45-1.91 0.84 0.39-1.80 
Gestational diabetes 80 (10.8) 304 (8.2) 1.36 1.05-1.78 1.35 1.04-1.77 
*Matched analysis without adjustment **Matched data adjusted by maternal age(categorized), parity, smoking status. 
 -No sufficient data for matched analysis.  
 
 
Table 4. Odds ratios for childhood cancer in the offspring, stratified by the cancer subtype. 
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Novelty & Impact Statement: 
 
Only a small fraction of early-onset childhood cancers are linked to hereditary factors, suggesting that 
environmental exposures, particularly in the mother, significantly impact childhood cancer risk. A 
potentially important, though understudied environmental factor is maternal diabetes. This 
investigation of nationwide population-based registry data shows that maternal diabetes is associated 
with an elevated risk of childhood cancer in offspring. Offspring born to mothers diagnosed with 
gestational diabetes were at increased risk of childhood leukemia and certain solid tumors in particular. 
Further investigation is needed to determine whether diabetes medications taken during pregnancy can 
reduce cancer risk in offspring. 
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